發(fā)布時(shí)間：2018-05-03 09:11

  本文選題：氯雷他定 + 生理性海水��； 參考：《中國(guó)藥房》2017年14期

【摘要】：目的:探討氯雷他定口服聯(lián)合生理性海水鼻腔沖洗治療間歇性變應(yīng)性鼻炎(AR)的臨床效果及安全性。方法:選取河北醫(yī)科大學(xué)第二醫(yī)院2013年1月-2015年6月收治的間歇性AR患者共300例,按抽簽法分為A、B、C組,各100例。A組患者給予氯雷他定片10 mg,po,qd;B組患者采用生理性海水鼻腔噴霧器進(jìn)行鼻腔沖洗,早晚各沖洗1次;C組患者給予氯雷他定口服聯(lián)合生理性海水鼻腔沖洗。3組患者療程均為28 d。比較3組患者的臨床療效,治療前后癥狀體征積分、呼吸功能指標(biāo)和炎癥因子指標(biāo)水平,以及隨訪12個(gè)月期間的臨床復(fù)發(fā)情況。結(jié)果:A、B、C組患者的總有效率分別為80.00%、78.00%、96.00%,C組顯著高于A、B組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,3組患者的癥狀體征積分、呼吸功能指標(biāo)和炎癥因子水平比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,3組患者的癥狀體征積分、最大呼氣流速(PEF)晝夜變異率、腫瘤壞死因子α、γ干擾素和白細(xì)胞介素(IL)-4水平均顯著低于治療前,PEF和IL-12水平均顯著高于治療前,且C組患者各指標(biāo)水平均顯著優(yōu)于A、B組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。A、B、C組患者的臨床復(fù)發(fā)率分別為21.00%、23.00%、6.00%,C組顯著低于A、B組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。A、B組患者上述所有指標(biāo)比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:氯雷他定口服聯(lián)合生理性海水鼻腔沖洗治療間歇性AR可有效減輕患者鼻部癥狀體征,改善患者呼氣功能,下調(diào)機(jī)體炎癥反應(yīng)水平,并有助于降低遠(yuǎn)期復(fù)發(fā)風(fēng)險(xiǎn)。
[Abstract]:Objective: to investigate the clinical efficacy and safety of oral loratadine combined with physiologic sea water nasal irrigation in the treatment of intermittent allergic rhinitis (ARL). Methods: a total of 300 intermittent AR patients treated in the second Hospital of Hebei Medical University from January 2013 to June 2015 were selected and divided into two groups according to the drawing of lots. One hundred patients in group A were treated with loratadine 10 mg / kg poqdtadine B group, and the patients in group B were treated with a physiological seawater nasal spray apparatus for nasal cavity irrigation. The course of treatment in group C was 28 days after oral administration of loratadine and physiologic nasal cavity irrigation. The clinical efficacy, the score of symptoms and signs, the index of respiratory function and inflammatory factors before and after treatment were compared among the three groups, and the clinical recurrence during the 12 months follow-up was compared. Results the total effective rate of group C was 80.000.The total effective rate of group C was significantly higher than that of group A B, and the difference was statistically significant (P 0.05). Before treatment, there was no significant difference in the scores of symptoms and signs, respiratory function index and inflammatory factor level between the three groups, and the diurnal variation rate of symptom and sign score, maximum expiratory flow rate (PEF), and the level of inflammatory factors in the three groups were not significantly different before and after treatment. The levels of tumor necrosis factor 偽, interferon 緯 and interleukin-4 were significantly lower than those before treatment and the levels of IL-12 were significantly higher in group C than those in group A and B, and the levels of each index in group C were significantly higher than those in group A and B. There were significant differences in the clinical recurrence rate of patients in group C (P 0.05) and group A (P 0.05). The clinical recurrence rate of group C was 21.000.23.00 and the value of group C was significantly lower than that of group A and B, and the difference was statistically significant (P 0.05). There was no significant difference in all the above indexes in group A (P 0.05) and group A (P 0.05), and there was no significant difference (P 0.05) between group C and group A (P 0.05). Conclusion: oral loratadine combined with physiologic sea water nasal irrigation can effectively reduce nasal symptoms and signs, improve expiratory function, down-regulate the level of inflammation, and help to reduce the long-term risk of recurrence.
【作者單位】： 河北醫(yī)科大學(xué)第二醫(yī)院耳鼻咽喉二科;石家莊市鹿泉人民醫(yī)院兒科;石家莊市第三醫(yī)院耳鼻咽喉科;石家莊市第一醫(yī)院耳鼻咽喉科;
【分類號(hào)】：R765.21

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 梁思達(dá);;哮喘合并過(guò)敏性鼻炎服用氯雷他定[J];求醫(yī)問(wèn)藥;2011年12期

2 葉瑞艷;吳艷巧;汪柳燕;;二丙酸倍氯米松鼻噴霧劑聯(lián)合氯雷他定治療常年性變應(yīng)性鼻炎臨床研究[J];中國(guó)傷殘醫(yī)學(xué);2013年08期

3 趙敏;;中藥結(jié)合氯雷他定治療喉源性咳嗽73例臨床觀察[J];中國(guó)實(shí)用醫(yī)藥;2013年06期

4 黃劍輝;;氯雷他定與氯苯那敏臨床治療評(píng)價(jià)分析[J];北方藥學(xué);2013年03期

5 潘家權(quán);綜合治療春季卡他性結(jié)膜炎臨床效果分析[J];寧夏醫(yī)學(xué)雜志;2004年03期

6 焦江;;氯雷他定聯(lián)合白芍總苷治療常年性變應(yīng)性鼻炎的療效觀察[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2012年06期

7 吳逢波;秦雯霞;徐s，

本文編號(hào)：1837898